Trial Information

Velcade (Bortezomib for Injection) Observational Study

This is a national, multi-center (study conducted in multiple sites), non-interventional (a
scientific study where one or more investigators monitor one or more patients being treated
with the same medication), observational study (a scientific study to make a clear and easy
understanding of the cause and effect relationship) of Chinese Multiple Myeloma patients
treated with Velcade. The study consists of 3 phases, including, screening phase, treatment
phase, and follow up phase. In the screening phase, data will be collected on the basis of
patient's demographic status, components of disease severity assessment, and potential
prognostic factors. Data on prior cancer treatments will be collected retrospectively at
baseline for patients receiving cancer treatment prior to receiving Velcade. In the
treatment phase, Velcade is administered intravenously for a 2-week treatment period
followed by a 10-day rest period. Each treatment cycle consists of 21 days. Prospective (in
which the participants are first identified and then followed forward as time passes)
observational data will be collected during treatment with Velcade. In the follow up phase,
patients will be followed for up to three years to document long-term survival data. For
patients who reinitiate Velcade, data collection should follow Velcade treatment period
documentation process. Safety evaluations will be based on the incidence, intensity, and
types of adverse events. The total duration of the study is set prospectively for three
years from the date of the patients' initiation of Velcade.